University can claim sovereign immunity in cancer treatment suit, rules Federal Circuit

The dispute arises from the biotechnology company Gensetix’s acquisition of exclusive licencing of US patent numbers 8,728,806 and 9,333,248 from the University of Texas in 2014.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Illumina ordered to recall products after German patent ruling

16 July 2026 A Munich court ruled that Illumina infringed a rival’s DNA sequencing patents, handing the challenger an early victory in a dispute that is playing out across Europe and the US.

Biotech

Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer

15 July 2026 French drugmaker's Translate Bio unit accuses COVID rivals of infringing core lipid nanoparticle and mRNA purification patents, seeking damages from vaccines worth billions.

Biotech

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

10 July 2026 Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.

More features

Illumina ordered to recall products after German patent ruling

Goodwin launches San Diego office with senior life sciences hire

Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

IP Federation elects Philips licensing leader as new president

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

Exelixis opens two-front patent dispute over Cabometyx copies

University can claim sovereign immunity in cancer treatment suit, rules Federal Circuit

More on this story

Editor's picks

Editor's picks

More features